share_log

Eli Lilly and Co | PX14A6G: Notice of exempt solicitation

Eli Lilly and Co | PX14A6G: Notice of exempt solicitation

礼来 | PX14A6G：豁免招标通知
美股sec公告 ·  03/28 12:23
Moomoo AI 已提取核心信息
Trinity Health, along with co-filers, has urged Eli Lilly and Co shareholders to vote for a proposal at the annual meeting on May 6, 2024, that would require the company to consider the impact on patient access when applying for secondary or tertiary patents. The proposal aims to address the issue of extended patent exclusivities, which can delay generic drug entry, limit patient access, and increase healthcare costs. Studies cited in the communication highlight the significant price increases for top brand name drugs, including Eli Lilly's Trulicity, and the use of patent systems by drugmakers to extend monopolies. The Federal Trade Commission has challenged the improper listing of patents in the FDA's 'Orange Book' and has scrutinized the use...Show More
Trinity Health, along with co-filers, has urged Eli Lilly and Co shareholders to vote for a proposal at the annual meeting on May 6, 2024, that would require the company to consider the impact on patient access when applying for secondary or tertiary patents. The proposal aims to address the issue of extended patent exclusivities, which can delay generic drug entry, limit patient access, and increase healthcare costs. Studies cited in the communication highlight the significant price increases for top brand name drugs, including Eli Lilly's Trulicity, and the use of patent systems by drugmakers to extend monopolies. The Federal Trade Commission has challenged the improper listing of patents in the FDA's 'Orange Book' and has scrutinized the use of patent thickets by pharmaceutical companies. The proposal does not seek to prohibit Eli Lilly from obtaining secondary and tertiary patents but to include patient access in the decision-making process. Trinity Health emphasizes the need for a policy change and reporting to ensure shareholders are informed of Eli Lilly's adoption of the policy.
Trinity Health及共同申报人敦促礼来公司股东在2024年5月6日的年会上投票通过一项提案，该提案将要求该公司在申请二级或三级专利时考虑对患者准入的影响。该提案旨在解决延长专利排他性问题，这可能会延迟仿制药的进入，限制患者准入，并增加医疗成本。来文中引用的研究突出表明，包括礼来公司的Trulicity在内的顶级品牌药品的价格大幅上涨，以及制药商使用专利制度来扩大垄断。联邦贸易委员会对FDA的 “橙皮书” 中专利的不当清单提出了质疑，并审查了制药公司使用专利灌木丛的情况。该提案的目的不是禁止礼来公司获得二级和三级专利，而是将患者准入纳入决策过程。Trinity Health强调需要进行政策变更和报告，以确保股东了解礼来公司采用该政策的情况。
Trinity Health及共同申报人敦促礼来公司股东在2024年5月6日的年会上投票通过一项提案，该提案将要求该公司在申请二级或三级专利时考虑对患者准入的影响。该提案旨在解决延长专利排他性问题，这可能会延迟仿制药的进入，限制患者准入，并增加医疗成本。来文中引用的研究突出表明，包括礼来公司的Trulicity在内的顶级品牌药品的价格大幅上涨，以及制药商使用专利制度来扩大垄断。联邦贸易委员会对FDA的 “橙皮书” 中专利的不当清单提出了质疑，并审查了制药公司使用专利灌木丛的情况。该提案的目的不是禁止礼来公司获得二级和三级专利，而是将患者准入纳入决策过程。Trinity Health强调需要进行政策变更和报告，以确保股东了解礼来公司采用该政策的情况。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息